COVID-19: Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis

Sponsor
Scentech Medical Technologies Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT04842708
Collaborator
(none)
43
1
2
12
3.6

Study Details

Study Description

Brief Summary

The objective of this study will be to evaluate the effect of vaccination on breath VOC content.

By capturing and analyzing the breath of anti-COVID-19 vaccinated subjects during the period of antibody production, the investigators will determine and quantify all the compounds associated with the body reaction to the COVID-19 antigen.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: vaccination against COVID19
N/A

Detailed Description

The objective of this study will be to evaluate the effect of vaccination on breath VOC content.

By capturing and analyzing the breath of anti-COVID-19 vaccinated subjects during the period of antibody production, the investigators will determine and quantify all the compounds associated with the body reaction to the COVID-19 antigen.

Rapidly growing serological evidence shows that IgM, IgG, and IgA antibodies against the S or N proteins evolve rapidly in the serum of asymptomatic as well as symptomatic COVID-19 patients within a week of infection or symptom onset and stay elevated with progressing disease.

Since the standard serology testing at Shamir Medical center tracks the presence of IgG only, those serologic tests will be conducted before and 48 hours following the second vaccination dose.

Nevertheless, since IgM antibodies are known to be produced by four to seven days following the first dose of vaccination, although IgM serology testing cannot be performed, the investigators are interested in sampling breath at this time range, in order for them to correlate it with the changes in the subjects' physiologic condition.

Since this is an unknown metabolic volatile compound mixture, the goal will be to identify compounds and quantify them with a high level of precision and subsequently correlate them with the disease.

Study Design

Study Type:
Interventional
Actual Enrollment :
43 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis
Actual Study Start Date :
Dec 24, 2020
Actual Primary Completion Date :
Dec 24, 2021
Actual Study Completion Date :
Dec 24, 2021

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Healthy Volunteers that are not to be vaccinated against COVID19

Healthy Volunteers that are not eligible to be vaccinated against COVID19

Experimental: Healthy Volunteers that are assigned to be vaccinated against COVID19

Healthy Volunteers that are eligible to be vaccinated against COVID19

Diagnostic Test: vaccination against COVID19
subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.

Outcome Measures

Primary Outcome Measures

  1. Association between breath VOCs and IgG in blood following second vaccination dose. [Through the study completion, up to 1 month.]

    VOCs profile found in breath will be correlatated with IgG profile in blood.

Secondary Outcome Measures

  1. Association between VOCs profile and participants' clinical or demographic characteristics [Through the study completion, up to 1 month.]

    Identify potential exhaled biomarkers association with participants' characteristics (age, gender, symptoms-severity, etc.)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 18 to 75 years at the time of consent

  • Capable of understanding written and/or spoken language

  • Able to provide informed consent

  • Assigned to undergo anti-COVID-19 vaccination

Exclusion Criteria:
  • Age under 18 years old

  • Under guardianship or deprived of liberty

  • Pregnant or lactating woman

  • Not eligible for anti-COVID-19 vaccination

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shamir Medical Center Be'er Ya'aqov Israel

Sponsors and Collaborators

  • Scentech Medical Technologies Ltd

Investigators

  • Principal Investigator: Shai Efrati, MD, Shamir Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Scentech Medical Technologies Ltd
ClinicalTrials.gov Identifier:
NCT04842708
Other Study ID Numbers:
  • Cov-2-SMC-V-2020
First Posted:
Apr 13, 2021
Last Update Posted:
Feb 7, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 7, 2022